Deandrea Silvia, Tidone Enrica, Bellini Aldo, Bisanti Luigi, Leonardo Nico Gerardo, Silvestri Anna Rita, Consonni Dario
European Commission, Directorate-General Joint Research Centre (JRC), Ispra VA, Italy.
Agenzia di Tutela della Salute della Citta Metropolitana di Milano, Milano, Italy.
BMJ Open Qual. 2018 Mar 22;7(1):e000299. doi: 10.1136/bmjoq-2017-000299. eCollection 2018.
A multidisciplinary working group applied the Healthcare Failure Mode and Effects Analysis (HFMEA) approach to the flow of kits and specimens for the first-level test of a colorectal cancer screening programme using immunochemical faecal occult blood tests.
HFMEA comprised four steps: (1) identification and mapping of the process steps (subprocesses); (2) analysis of failure modes and calculation of the risk priority numbers (RPNs); (3) identification of corrective actions; and (4) follow-up and evaluation of corrective actions.
The team identified 9 main failure modes, 12 effects and 34 associated causes. RPN scores ranged from 2 to 96. Failure modes within the first five positions in the ranking list ordered by RPN concerned: 'degraded haemoglobin in the specimen', 'mixed-up kits' and 'anonymous specimen'. All of these could lead to false-negative results and/or subjects with positive tests not being recalled for assessment. The team planned corrective actions for those failure modes. As a result, the follow-up of corrective actions showed a significant decrease in the proportion of anonymous kits from 11.6 to 4.8 per 1000 (relative reduction of 59%). The HFMEA exercise led to a reduction in: missed positive tests; missed cancer and high-risk adenomas; complaints about the communication of test results to a person who never did the test; and false-negative results due either to haemoglobin degradation or an expired sampling tube.
HFMEA is a useful tool for reducing errors in colorectal cancer screening programmes using faecal occult blood tests and is characterised by a straightforward interpretation of results and ease of communication to healthcare managers and decision makers.
一个多学科工作小组将医疗失效模式与效应分析(HFMEA)方法应用于一项使用免疫化学粪便潜血试验的结直肠癌筛查项目一级检测的试剂盒和样本流程。
HFMEA包括四个步骤:(1)识别并绘制流程步骤(子流程);(2)分析失效模式并计算风险优先数(RPN);(3)识别纠正措施;(4)对纠正措施进行跟进和评估。
该团队识别出9种主要失效模式、12种影响及34个相关原因。RPN得分范围为2至96。按RPN排序的排名列表中前五位的失效模式涉及:“样本中血红蛋白降解”“试剂盒混淆”和“样本匿名”。所有这些都可能导致假阴性结果和/或检测呈阳性的受试者未被召回进行评估。该团队针对这些失效模式制定了纠正措施。结果,对纠正措施的跟进显示,匿名试剂盒的比例从每1000个中的11.6个显著降至4.8个(相对降低59%)。HFMEA活动使以下情况减少:漏检阳性检测;漏检癌症和高危腺瘤;对将检测结果告知从未进行检测的人的投诉;以及因血红蛋白降解或采样管过期导致的假阴性结果。
HFMEA是一种用于减少使用粪便潜血试验的结直肠癌筛查项目中错误的有用工具,其特点是结果解释直接,便于与医疗管理人员和决策者沟通。